NCT04366115View on ClinicalTrials.gov

Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 1, 2026

Primary Completion Date

December 1, 2031

Study Completion Date

March 1, 2032

Conditions
ARDSCovid19Influenza, Human
Interventions
DRUG

AVM0703

Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.

DRUG

Placebo

Single IV infusion in normal saline over 1 hour to patients.

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

AVM Biotechnology Inc

INDUSTRY